News
Oppenheimer Maintains Outperform on Biomea Fusion, Maintains $70 Price Target
3 Apr 24
News, Price Target, Analyst Ratings
JP Morgan Downgrades Biomea Fusion to Neutral, Lowers Price Target to $14
2 Apr 24
News, Downgrades, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $50 Price Target
1 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Truist Securities Reiterates Buy on Biomea Fusion, Maintains $55 Price Target
1 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Biomea Fusion Q4 EPS $(0.98) Misses $(0.85) Estimate
1 Apr 24
Earnings, Earnings Misses, News
Recap: Biomea Fusion Q4 Earnings
1 Apr 24
Earnings
Biomea Fusion Highlights Initial Data From The First Two Type 1 Diabetes Patients Dosed With BMF-219
1 Apr 24
Biotech, News, General
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $50 Price Target
6 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
6 Mar 24
News
Truist Securities Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $55
6 Feb 24
News, Price Target, Initiation, Analyst Ratings
Press releases
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1 Apr 24
Press Releases
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
1 Apr 24
Health Care, Press Releases, General
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
6 Mar 24
News, Press Releases
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24
Markets, Press Releases